Show simple item record

dc.contributor.authorMrázek, František
dc.contributor.authorSchneiderová, Petra
dc.contributor.authorKriegová, Eva
dc.contributor.authorRaida, Luděk
dc.contributor.authorKuba, Adam
dc.contributor.authorGajdoš, Petr
dc.contributor.authorKönigová, Nikola
dc.contributor.authorOnderková, Jana
dc.contributor.authorAmbrůzová, Zuzana
dc.date.accessioned2017-10-31T09:14:24Z
dc.date.available2017-10-31T09:14:24Z
dc.date.issued2016
dc.identifier.citationArchivum Immunologiae et Therapiae Experimentalis. 2016, vol. 64, suppl. 1, p. S55-S61.cs
dc.identifier.issn0004-069X
dc.identifier.issn1661-4917
dc.identifier.urihttp://hdl.handle.net/10084/120996
dc.description.abstractAllogeneic hematopoietic stem cell transplantation (aHSCT) is used as a curative treatment in severe hematological and immunological disorders. Despite clear improvement of the aHSCT outcome, substantial proportion of patients still suffers from severe complications, including graft-versus-host disease (GvHD). The aim of this study was, therefore, to identify inflammation-associated molecules deregulated in the early serum samples of the patients after aHSCT and nominate markers associated with particular aHSCT parameters/complications. Serum concentrations of 92 inflammation-associated proteins were measured in samples obtained from 80 aHSCT patients 14 days after transplantation and from 23 healthy control subjects by a novel sensitive proximity extension assay technology using Proseek Multiplex Inflammation I kit. Serum profiles of inflammatory proteins in patients after aHSCT were substantially different from those observed in control subjects and related to underlying disease status before transplantation. Particularly, the difference between aHSCT patients and controls reached significance level for 57 analytes (40 upregulated, 17 downregulated in aHSCT patients). The concentration of several markers was associated with the level of donor/recipient HLA match (TGF-alpha: P-corr = 0.025, HGF: p(corr) = 0.036) and with complete donor chimerism at day +30 after allografting (DNER: p(corr) = 0.042). None of the markers was significantly associated with acute and chronic GvHD after correction. More than half of investigated proteins significantly differed between the samples from aHSCT patients and healthy control subjects as a consequence of the "cytokine storm'' after aHSCT. Comparisons of patient's subgroups based on specific biological/clinical parameters revealed much less evident differences; nevertheless, we nominated several markers associated with the level of donor/recipient HLA match and post-transplant chimerism.cs
dc.language.isoencs
dc.publisherSpringercs
dc.relation.ispartofseriesArchivum Immunologiae et Therapiae Experimentaliscs
dc.relation.urihttps://doi.org/10.1007/s00005-016-0446-2cs
dc.rights© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2016cs
dc.subjecthematopoietic stem cell transplantationcs
dc.subjectgraft-versus-host diseasecs
dc.subjectprotein profilescs
dc.subjectbiomarkerscs
dc.subjectinflammationcs
dc.titleProfile of inflammation-associated proteins in early post-transplant samples of patients after allogeneic hematopoietic stem cell transplantation: a preliminary studycs
dc.typearticlecs
dc.identifier.doi10.1007/s00005-016-0446-2
dc.type.statusPeer-reviewedcs
dc.description.sourceWeb of Sciencecs
dc.description.volume64cs
dc.description.issuesuppl. 1cs
dc.description.lastpageS61cs
dc.description.firstpageS55cs
dc.identifier.wos000411337500005


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record